Black checkmark with a sparkle and a curved line underneath on a white background.
Company

JATT II Acquisition Corp.

Ticker
JATT
Sector
Industry
Report date
November 14, 2026
Valye AI Score

51

Moderate visibility
Recent developments
Recent developments summary

Recent developments include the merger forming Zura Bio Limited, financial results reporting, clinical trial discontinuation, and notable investor position changes.

Recent developments:
  • JATT II Acquisition Corp. merged with Zura Bio to form Zura Bio Limited in June 2022 [N5].
  • Zura Bio Limited reported third quarter 2026 financial results in October 2026 [N2].
  • Zura Bio Limited discontinued development of Tibulizumab for Hidradenitis Suppurativa after a Phase 2 trial missed endpoints in November 2026 [N1].
  • Hudson Bay Capital Management increased its position in JATT Acquisition Corp. in February 2023 [N3].
  • Magnetar Financial cut its stake in JATT Acquisition Corp. in February 2023 [N4].
  • The latest SEC 10-Q filing was submitted on November 13, 2026, with no material changes to risk factors disclosed [S1].
Overview

JATT II Acquisition Corp. is a special purpose acquisition company (SPAC) that completed a merger with Zura Bio to form Zura Bio Limited, a biopharmaceutical company focused on drug development. The company has reported financial results through SEC filings, showing ongoing investment in research and development activities. Liquidity metrics indicate a strong short-term financial position as of the latest quarter. The company faces typical risks associated with clinical trial outcomes and regulatory approvals in the pharmaceutical industry.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. JATT II Acquisition Corp. merged with Zura Bio to form Zura Bio Limited in 2022. The company reported a net loss of $493,908 for the quarter ended September 30, 2026, with a strong current ratio of 6.53 indicating liquidity. Recent news highlights include discontinuation of a drug candidate after a failed Phase 2 trial and active investor position changes.

Scenarios for JATT

Bull case model:

The company benefits from its merger with Zura Bio Limited, which brings a portfolio of drug candidates and ongoing clinical programs. Strong liquidity as indicated by a high current ratio supports operational flexibility. Investor interest, as evidenced by position changes from institutional investors, reflects engagement with the company's strategic direction. Continued progress in clinical development and successful regulatory milestones could enhance business visibility and value.

Bear case model:

The discontinuation of Tibulizumab development after a failed Phase 2 trial highlights the clinical and regulatory risks inherent in biopharmaceutical development. The company reported a net loss in the latest quarter, reflecting ongoing expenses without current revenue generation. Dependence on successful clinical outcomes and regulatory approvals creates uncertainty. Changes in investor positions may indicate varying confidence levels in the company's prospects. The absence of disclosed revenue and limited public financial data constrain comprehensive visibility into operational performance.

Moat:

The company's moat is primarily derived from its merger with Zura Bio Limited, which provides access to proprietary drug candidates and clinical development programs. The biopharmaceutical sector's high barriers to entry, including regulatory requirements and specialized expertise, contribute to the company's competitive positioning. However, the success of its drug pipeline and ability to navigate clinical and regulatory challenges remain critical to sustaining its moat.

Risks overview
Risks summary
The primary risk is the uncertainty inherent in clinical development outcomes and regulatory approvals, which directly affect the company's ability to generate future revenue and sustain operations.
Risks details:

• Clinical Trial Risk: Failure of clinical trials, such as the discontinuation of Tibulizumab after missing Phase 2 endpoints, can materially impact the company's drug development pipeline and future prospects.
• Financial Risk: The company reported a net loss and has no disclosed revenue, indicating ongoing expenses and reliance on financing or capital markets for operations.
• Regulatory Risk: Biopharmaceutical products require regulatory approvals which are uncertain and can delay or prevent commercialization.
• Market and Investor Sentiment Risk: Changes in institutional investor positions reflect varying market confidence, which can affect stock liquidity and valuation.

FINAL FORECAST FOR JATT

Final take one line
JATT II Acquisition Corp. has high visibility due to its merger with Zura Bio Limited, recent financial disclosures, and active investor interest, with key risks centered on clinical development and regulatory outcomes.
Final take 12 to 24 month view

Business trends: The company is focused on advancing its biopharmaceutical pipeline through Zura Bio Limited, with recent clinical trial discontinuations highlighting development challenges.
Execution milestones: Completion of the merger with Zura Bio, quarterly financial reporting, and managing investor relations are key milestones.
Key risks: Clinical trial failures, regulatory approval uncertainties, financial losses, and fluctuating investor sentiment remain significant risks.

Valye AI Visibility Research Score

Moderate visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

51
LLM visibility overview
LLM Visibility known facts
  • JATT II Acquisition Corp. merged with Zura Bio to form Zura Bio Limited as of June 2022.
  • The company operates in the biopharmaceutical sector, focusing on drug development through Zura Bio Limited.
  • Recent financial results for Zura Bio Limited were reported for the third quarter of 2026.
  • Zura Bio Limited discontinued development of Tibulizumab for Hidradenitis Suppurativa after a Phase 2 trial missed endpoints as of November 2026.
  • As of September 30, 2026, JATT II Acquisition Corp. reported current assets of $1,208,864 and current liabilities of $185,014, resulting in a current ratio of 6.53, indicating strong short-term liquidity.
  • Net income was negative $493,908 for the quarter ending September 30, 2026.
  • Basic and diluted earnings per share were both negative $0.05 for the quarter ending March 31, 2026.
  • There have been no material changes to the risk factors disclosed in the company's final prospectus for its Initial Public Offering as of the latest 10-Q filing on November 13, 2026.
  • Investor activity includes Hudson Bay Capital Management increasing its position and Magnetar Financial cutting its stake in JATT Acquisition Corp. in early 2023.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | Zura Bio Limited Discontinues Tibulizumab Development in Hidradenitis Suppurativa After Phase 2 Trial Misses Endpoints | https://www.nasdaq.com/articles/zura-bio-limited-discontinues-tibulizumab-development-hidradenitis-suppurativa-after-phase
  • N2 | 2026-10-27 | www.nasdaq.com | Zura Bio Limited Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/zura-bio-limited-reports-third-quarter-2026-financial-results
  • N3 | 2023-02-06 | www.nasdaq.com | Hudson Bay Capital Management Increases Position in JATT Acquisition Corp - (JATT) | https://www.nasdaq.com/articles/hudson-bay-capital-management-increases-position-in-jatt-acquisition-corp-jatt
  • N4 | 2023-02-02 | www.nasdaq.com | Magnetar Financial Cuts Stake in JATT Acquisition Corp - (JATT) | https://www.nasdaq.com/articles/magnetar-financial-cuts-stake-in-jatt-acquisition-corp-jatt
  • N5 | 2022-06-17 | www.nasdaq.com | JATT Acquisition, Zura Bio To Merge To Form Zura Bio Limited | https://www.nasdaq.com/articles/jatt-acquisition-zura-bio-to-merge-to-form-zura-bio-limited
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine